CSF biomarkers and plasma p‐tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design

Reduced [18F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter

(2021) Alexis Moscoso et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease

(2021) Alexis Moscoso et al.   JAMA Neurology

Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach

(2021) Sarah K. Royse et al.   Alzheimers Research & Therapy

Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia

(2020) Shorena Janelidze et al.   NATURE MEDICINE

Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration

(2020) Elisabeth H. Thijssen et al.   NATURE MEDICINE

Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts

(2020) Thomas K Karikari et al.   LANCET NEUROLOGY

A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease

(2020) Nicolas R. Barthélemy et al.   NATURE MEDICINE

Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes

(2020) Adam S. Fleisher et al.   JAMA Neurology

Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease

(2020) Niklas Mattsson-Carlgren et al.   Science Advances

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline

(2020) Juan Lantero Rodriguez et al.   ACTA NEUROPATHOLOGICA

Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration

(2020) Alberto Benussi et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Predicting future rates of tau accumulation on PET

(2020) Clifford R Jack et al.   BRAIN

Association is not prediction: a landscape of confused reporting in diabetes – a systematic review

(2020) Tibor V. Varga et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

White matter hyperintensities are associated with subthreshold amyloid accumulation

(2020) Alexis Moscoso et al.   NEUROIMAGE

Association of Initial β-Amyloid Levels With Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive Impairment

(2020) David S. Knopman et al.   JAMA Neurology

The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects

(2020) Ruben Smith et al.   BRAIN

Time course of phosphorylated-tau181 in blood across the Alzheimer’s disease spectrum

(2020) Alexis Moscoso et al.   BRAIN

Longitudinal tau accumulation and atrophy in aging and alzheimer disease

(2019) Theresa M. Harrison et al.   ANNALS OF NEUROLOGY

A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease

(2019) Francesco Panza et al.   Nature Reviews Neurology

Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease

(2019) Rik Ossenkoppele et al.   NEUROLOGY

A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia

(2019) Michael J Pontecorvo et al.   BRAIN

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

(2019) Oskar Hansson et al.   Alzheimers Research & Therapy

Tau-positron emission tomography correlates with neuropathology findings

(2019) Val J. Lowe et al.   Alzheimers & Dementia

Establishment of Best Practices for Evidence for Prediction

(2019) Russell A. Poldrack et al.   JAMA Psychiatry

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts

(2018) Oskar Hansson et al.   Alzheimers & Dementia

Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials?

(2018) Oskar Hansson et al.   BRAIN

Longitudinal tau PET in ageing and Alzheimer’s disease

(2018) Clifford R Jack et al.   BRAIN

Tau-targeting therapies for Alzheimer disease

(2018) Erin E. Congdon et al.   Nature Reviews Neurology

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology

(2018) Renaud La Joie et al.   Alzheimers & Dementia

AV-1451 PET imaging of tau pathology in preclinical Alzheimer disease: Defining a summary measure

(2017) Shruti Mishra et al.   NEUROIMAGE

Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease

(2017) Anne Maass et al.   NEUROIMAGE

Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1–42) in human cerebrospinal fluid

(2016) Tobias Bittner et al.   Alzheimers & Dementia

The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015

(2015) William J. Jagust et al.   Alzheimers & Dementia

The Centiloid Project: Standardizing quantitative amyloid plaque estimation by PET

(2015) William E. Klunk et al.   Alzheimers & Dementia

The Alzheimer’s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans

(2015) Ju-Hee Kang et al.   Alzheimers & Dementia

Cortical tau load is associated with white matter hyperintensities

(2015) Kirsty E. McAleese et al.   Acta Neuropathologica Communications

Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid

(2013) Susan M. Landau et al.   ANNALS OF NEUROLOGY

National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease

(2012) Bradley T. Hyman et al.   Alzheimers & Dementia

Amyloid deposition, hypometabolism, and longitudinal cognitive decline

(2012) Susan M. Landau et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

(2010) Kaj Blennow et al.   Nature Reviews Neurology